Details of the Drug Reposition

General Information of This Drug (ID: DMRKU0L)

Drug Name
GS-5718   DMRKU0L
Synonyms
920036-34-6; tert-Butyl 3-iodo-1H-pyrazolo[3,4-b]pyridine-1-carboxylate; 1-BOC-3-IODO-1H-PYRAZOLO[3,4-B]PYRIDINE; tert-butyl 3-iodopyrazolo[3,4-b]pyridine-1-carboxylate; SCHEMBL3606964; OKKLWSNHFSFXEM-UHFFFAOYSA-N; AMY21637; MFCD13183727; AKOS022178093; GS-5718; PB26872; CS-0048281; FT-0702852; A860172; tert-Butyl3-iodo-1H-pyrazolo[3,4-b]pyridine-1-carboxylate; 1H-Pyrazolo[3,4-b]pyridine-1-carboxylicacid,3-iodo-,1,1-diMethylethylester; 1H-PYRAZOLO[3,4-B]PYRIDINE-1-CARBOXYLIC ACID, 3-IODO-, 1,1-DIMETHYLETHYLESTER
Drug Type
Small molecule
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Rheumatoid arthritis DISTSB4J FA20 Phase 2 [1]
------------------------------------------------------------------------------------
1 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Cutaneous lupus erythematosus DISOIX6L EB5Z Phase 1 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT05165771) A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Proof-of-Concept Study to Evaluate Safety, Tolerability, and Efficacy of GS-5718 on Background Therapy With Conventional Synthetic Disease-modifying Antirheumatic Drug(s) (csDMARDs) in Participants With Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic DMARD(s) Treatment. U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT04809623) A Randomized, Blinded, Placebo-Controlled, Phase 1b Study of GS-5718 in Subjects With Cutaneous Lupus Erythematosus (CLE). U.S.National Institutes of Health.